For retinal specialists delivering viral vectors, advanced needle design is no longer a minor detail—it is a clinical imperative for therapeutic accuracy.
As retinal gene therapies transition from a futuristic paradigm into everyday clinical practice, ophthalmologists face a unique structural hurdle: delivering precise micro-volumes without altering the therapeutic agent itself. When handling delicate biological payloads & adeno-associated viral (AAV) vectors, traditional delivery systems introduce mechanical variables that can directly compromise the exact therapeutic dose reaching the target tissue (1).
To eliminate these clinical wildcards, specialized medical engineering—specifically TSK’s ophthalmic approved STERiJECT Low Dead Space (LDS) needles—is quickly becoming an essential asset in the operating room. Explicitly 510(k) cleared for ophthalmic use, these dedicated devices bridge the gap between benchtop genetic precision and true clinical reproducibility.
Specialized Hub Geometry: Maximizing Volume and Optimizing Flow
In intravitreal delivery and targeted ocular injections, the volume is exceptionally minute. Traditional needle hubs present a geometric "dead space" that traps fluid. For clinicians, this disrupts volume calculation and risks delivering a sub-therapeutic dose. TSK’s 510(k) cleared STERiJECT LDS needles feature a specialized hub design that minimizes dead space to nearly zero, ensuring that the exact calculated therapeutic dose actually exits the syringe.
However, the advantages of this engineered hub extend beyond volume retention. Standard hubs allow for chaotic, turbulent fluid dynamics as the vector solution transitions from the syringe barrel into the needle. TSK’s specialized hub geometry restricts this internal space to streamline fluid dynamics. By minimizing transitional volume and smoothing the flow path, it significantly decreases fluid shear stress and prevents destructive particle collisions within the hub itself, protecting viral capsids before they even reach the needle lumen.
Smooth Lumens: Eliminating Secondary Stress and Adhesion
Once past the hub, the physical journey through the needle bore poses additional threats to structural integrity (2). Standard manufacturing can leave microscopic irregularities inside the needle, leading to two major clinical complications:
· Shear Stress Deactivation: Forcing complex viral capsids through narrow gauges under pressure creates intense fluid shear stress. High shear can structurally deform or deactivate the viral vectors (3), rendering a portion of the therapy non-functional before it ever reaches the target tissue. TSK’s exceptionally smooth internal lumen minimizes fluid turbulence, protecting the delicate capsids from mechanical degradation.
· Preventing Particle Adherence: Viral particles have a natural tendency to stick to rough internal surfaces. Standard needle walls can strip vital vectors out of the suspension via surface adhesion, inadvertently lowering the delivered viral titer. TSK’s polished internal surface area prevents particle sticking, ensuring the suspension maintains its intended concentration throughout the entire path of delivery.
The Clinical Bottom Line
For the treating physician, successful gene therapy relies on complete predictability. If a viral vector is sheared, collided, or trapped in transit, the patient receives an unintended sub-therapeutic dose. By incorporating ophthalmic approved STERiJECT LDS needles with advanced hub architecture and a smooth internal lumen, ophthalmologists can safeguard capsid integrity from hub to tip, guaranteeing that the prescribed dose is precisely what reaches the eye.
References
- Rowe-Rendleman CL, Durazo SA, Kompella UB, Rittenhouse KD, Di Polo A, Weiner AL, et al. Drug and gene delivery to the back of the eye: From bench to bedside. Investig Ophthalmol Vis Sci. 2014;55(4):2714-36.
- Butt M, Zaman M, Ahmad A, Khan R, Mallhi T, Hasan M, et al. Appraisal for the potential of viral and nonviral vectors in gene therapy: A review. Genes. 2022;13(8):1370.
- Mullagulova AI, Timechko EE, Solovyeva VV, Yakimov AM, Ibrahim A, Dmitrenko DD, et al. Adeno-associated viral vectors in the treatment of epilepsy. Int J Mol Sci. 2024;25(22):12081.
